51 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
.
Cohort 2 of the SPEARHEAD-1 trial has completed recruitment and has an overall response rate nearly identical to Cohort 1 (data will be reported when
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
for the treatment of synovial sarcoma. Cohort 2 of the SPEARHEAD-1 trial has completed recruitment.
Data presentations
ASGCT: Translational analyses
8-K
EX-99.1
dk1gkdv6523csaran5
14 Mar 22
Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
8:06am
8-K
EX-99.1
19uea3d5f14c
13 Sep 21
Other Events
7:08am
8-K
EX-99.1
aew vj8gw4wv1e
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
smahh8qmohl3htgl
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
t00umdb
29 May 20
Regulation FD Disclosure
7:42am